Valproic acid pathway: pharmacokinetics and pharmacodynamics. - Wikidata - awgldk - TriplyDB

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

http://www.wikidata.org/entity/Q34327652

about

Fragile X syndrome: A review of clinical management Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.Hyperammonemia associated with valproic acid concentrations.Postnatal treatment using curcumin supplements to amend the damage in VPA-induced rodent models of autism The Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression.Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis.Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.Network Reconstruction Reveals that Valproic Acid Activates Neurogenic Transcriptional Programs in Adult Brain Following Traumatic Injury.Pharmacogenomics and histone deacetylase inhibitors.Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.Molecular network-selected pharmacogenomics in a case of bipolar spectrum disorder.A Systematic Review of Population Pharmacokinetics of Valproic Acid.Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid.Environmental, genetic and epigenetic contributions to cocaine addiction.The pharmacogenomics of valproic acid.Clinical Importance of Monitoring Unbound Valproic Acid Concentration in Patients with Hypoalbuminemia.Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese.Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.Glutamate transporters, EAAT1 and EAAT2, are potentially important in the pathophysiology and treatment of schizophrenia and affective disorders.

P2860

Q28076950-1B078426-FB76-46B5-82A5-5B4778C0D4D6 Q31111176-6769412E-4E8C-4DD6-8242-7DB8C2EC3D1A Q33608984-23CBC1AC-3DB0-40AC-9C4B-26D316FB5BB9 Q33654915-29D8FC5E-8EEC-4E09-8433-A988C3D901C9 Q33794860-6A63C6A5-8C92-479E-A13A-7BC20267126C Q34456179-34C9FA08-9309-47C1-BBAB-E158BD30A539 Q35814413-E13BBE40-1D07-41B1-A95C-E1576745A2DA Q38242979-AF9835AE-D7FA-4370-870A-1D4B6C487C2B Q38587724-CB5A3DF5-C3F6-470C-819C-016CEC88F890 Q38921974-62AC34B9-EF92-424E-9040-5E111B902E82 Q38987332-8E0A5022-BA2E-4CCA-85A7-70BB100612EC Q41533636-FEB60C60-5A97-4373-A8C3-87D4B6D36D74 Q42128344-F673A036-1F3D-48AD-9F52-71BC4F9DF3C9 Q47573171-8439491E-6A26-4DA1-ABB4-CA41C7A1A511 Q47735769-0FF43D97-5E40-41DF-8CA5-95EA52601EE3 Q49219661-73FB02AD-5E94-4E47-9BB5-F2C24BD03459 Q49825261-467F9EE0-AD24-4986-8E27-AAFEC7D2AEC3 Q49912035-911E6CDC-17DB-4119-AE87-9208BF591997 Q50212278-1D23F928-719D-471B-8428-FDA5DCBD5C2B Q50962805-F2D7D505-4E2B-4E2D-A3BF-BF17E226073E Q51285380-08082FA5-150E-449F-8169-5EDA598CB6FD Q53521796-75DE23D5-D8C9-4E6B-AB32-75301B3FC073 Q55505650-48D67675-90BD-4445-B501-5BD69A692F78

P2860

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

http://www.wikidata.org/entity/Q34327652

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@ast

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@en

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@nl

type

label

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@ast

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@en

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@nl

prefLabel

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@ast

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@en

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@nl

P1433

Q34327652-537FAB06-52F6-46D7-9925-CA999CF01280

P1476

Q34327652-61F42A92-C63C-4C59-9AFF-D42ADAA97570

P2093

Q34327652-2EBCC1C6-7282-4354-8AC5-68A7BA204AE9

Q34327652-3008DE13-8C7E-4E44-8230-DF8F0B979FB9

Q34327652-326535E1-6BA9-48EC-A688-D532785817D9

Q34327652-4F5088C8-ED27-49AE-9136-0BE48028943D

Q34327652-7F1A3C88-CA36-47A2-8F29-6BFE1AC929A0

Q34327652-D442233C-00BD-49FF-87C9-20196C58DD86

Q34327652-FE75B032-B985-4D48-80C2-87E25F1271D3

P2860

Q34327652-01E79777-563A-4CA9-BA19-10E7FDB2B8EB

Q34327652-03425B39-B3AE-4F15-9B95-08095EEE6D93

Q34327652-04843635-F96E-49F4-ADE0-5AACBF24A1EF

Q34327652-0F6BF5D2-08BE-4D0C-8585-43F259425CFF

Q34327652-10B2FB2E-D55C-4F30-8FD8-F2B8E2051F2C

Q34327652-3D2DAE43-B546-4EF3-A941-A1F92BDCC37C

Q34327652-41A4C79C-4A21-40B0-99F1-8251CE7E513E

Q34327652-59FB4FA4-D2FB-4A28-8826-04E43EB1194C

Q34327652-5D0B130C-308D-4995-8796-FF7933A0CC32

Q34327652-5E6F691B-D974-47AA-9A36-6946CF2F6F59

P304

Q34327652-86842EEC-2535-4914-85BD-E85D8D238FF8

P31

Q34327652-A94D82D6-B85A-4F81-8820-4BEA8B0D4F6E

P356

Q34327652-746E3CE2-6A03-48DD-8869-A3C2BD952EE0

P433

Q34327652-4E94C790-5632-4C46-80F8-FA0F0122B57D

P478

Q34327652-E7D07D34-2108-4A88-8701-24379ACED955

P50

Q34327652-C7D8B89E-E6DA-4BB4-8AC8-BEAD5B158980

P577

Q34327652-A9837521-EE1E-4BDE-B89F-A2D7099D5AC0

P698

Q34327652-C38E39EA-4731-4870-A0DD-E7648D2278CF

P932

Q34327652-EA3ABE91-91E7-4CC7-AB33-B0336D3E2229

P356

FPC.0B013E32835EA0B2

P1433

Pharmacogenetics and Genomics

P1476

Valproic acid pathway: pharmacokinetics and pharmacodynamics.

@en

P2093

Angela K Birnbaum

http://www.w3.org/2001/XMLSchema#string

Caroline F Thorn

http://www.w3.org/2001/XMLSchema#string

J Steven Leeder

http://www.w3.org/2001/XMLSchema#string

Jatinder K Lamba

http://www.w3.org/2001/XMLSchema#string

Teri E Klein

http://www.w3.org/2001/XMLSchema#string

Wen Song

http://www.w3.org/2001/XMLSchema#string

Yogita Ghodke-Puranik

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular and therapeutic potential and toxicity of valproic acid

Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans

The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase

Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes

Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid

The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.

P304

236-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E32835EA0B2

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23407051

http://www.w3.org/2001/XMLSchema#string

P932

3696515

http://www.w3.org/2001/XMLSchema#string